Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2022-502050-14-00 | Other Identifier | EU CT |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to other therapies.
Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide.
Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PK Cohort 1: SS1 | Experimental | Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2. |
|
| PK Cohort 1: SS2 Dose A | Experimental | Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
|
| PK Cohort 1: SS2 Dose B | Experimental | Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
|
| PK Cohort 1: SS3 Dose A | Experimental | Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Risankizumab | Drug | Intravenous (IV) Infusion |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission | PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. | At 64 weeks |
| Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per Simple Endoscopic Score for Crohn's Disease (SES-CD) | The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). | At 64 weeks |
| Cohorts 1 & 2: Maximum Observed Serum Concentration (Cmax) of Risankizumab | Cmax of risankizumab | Up to approximately Week 64 |
| Cohorts 1 & 2: Time to Cmax (Tmax) of Risankizumab | Tmax of risankizumab | Up to approximately 64 weeks |
| Cohorts 1 & 2: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Risankizumab | AUCtau of risankizumab | Up to approximately 64 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Cohort 3 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission | PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
History of hereditary fructose intolerance (a rare genetic condition) or an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class
Any of the following medical disorders:
Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD.
A diagnosis of CD prior to 2 years of age.
A diagnosis or suspected diagnosis of a primary immunodeficiency.
Currently known complications of CD such as:
Ostomy or ileoanal pouch.
Diagnosis of short gut or short bowel syndrome.
Surgical bowel resection within the past 3 months prior to Baseline (excluding gastrointestinal surgeries which are not bowel resections such as appendectomy or ostomy closure), or a history of >3 bowel resections.
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| ABBVIE CALL CENTER | Contact | 844-663-3742 | abbvieclinicaltrials@abbvie.com |
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Phoenix Children's Hospital /ID# 255766 | Recruiting | Phoenix | Arizona | 85016-7710 | United States | |
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Not provided
Not provided
Not provided
Not provided
Not provided
| PK Cohort 1: SS3 Dose B |
| Experimental |
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
|
| PK Cohort 2: SS1 | Experimental | Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2. |
|
| PK Cohort 2: SS2 Dose A | Experimental | Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
|
| PK Cohort 2: SS2 Dose B | Experimental | Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
|
| PK Cohort 2: SS3 Dose A | Experimental | Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
|
| PK Cohort 2: SS3 Dose B | Experimental | Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
|
| Expansion Cohort 3: SS1 | Experimental | Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2. |
|
| Expansion Cohort 3: SS2 Dose A | Experimental | Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
|
| Expansion Cohort 3: SS2 Dose B | Experimental | Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
|
| Expansion Cohort 3: SS3 Dose A | Experimental | Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
|
| Expansion Cohort 3: SS3 Dose B | Experimental | Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
|
| Risankizumab | Drug | Subcutaneous (SC) Injection |
|
|
| At 12 weeks |
| Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD | The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). | At 12 weeks |
| Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD | The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. | At 12 weeks |
| Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD | The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. | At 64 weeks |
| Cohort 3 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI | PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit. | At 64 weeks |
| Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving PCDAI Clinical Remission | PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. | At 64 weeks |
| Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per SES-CD | The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). | At 64 weeks |
| Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission | PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. | At 12 weeks |
| Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD | The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). | At 12 weeks |
| Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD | The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. | At 12 weeks |
| Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD | The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. | At 64 weeks |
| Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI | PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit. | At 64 weeks |
| Arkansas Children's Hospital /ID# 255762 |
| Recruiting |
| Little Rock |
| Arkansas |
| 72202 |
| United States |
| UCSF Benioff Children's Hospital - Oakland /ID# 258327 | Recruiting | Oakland | California | 94609 | United States |
| Children's Hospital Colorado - Aurora /ID# 255764 | Recruiting | Aurora | Colorado | 80045 | United States |
| Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437 | Recruiting | Orlando | Florida | 32806-1141 | United States |
| Indiana University Health Riley Hospital for Children /ID# 256454 | Recruiting | Indianapolis | Indiana | 46202 | United States |
| Massachusetts General Hospital /ID# 255767 | Recruiting | Boston | Massachusetts | 02114 | United States |
| MNGI Digestive Health, P. A. /ID# 255366 | Recruiting | Minneapolis | Minnesota | 55413-2195 | United States |
| Goryeb Childrens Hospital /ID# 256452 | Recruiting | Morristown | New Jersey | 07960 | United States |
| Icahn School of Medicine at Mount Sinai /ID# 254880 | Recruiting | New York | New York | 10029 | United States |
| Cleveland Clinic - Cleveland /ID# 256453 | Recruiting | Cleveland | Ohio | 44195 | United States |
|
| Uza /Id# 255114 | Recruiting | Edegem | Antwerpen | 2650 | Belgium |
| Cliniques Universitaires UCL Saint-Luc /ID# 255108 | Recruiting | Brussels | Brussels Capital | 1200 | Belgium |
| Universitair Ziekenhuis Brussel /ID# 255109 | Recruiting | Jette | Brussels Capital | 1090 | Belgium |
| Groupe Sante CHC - Clinique du MontLegia /ID# 255620 | Recruiting | Liège | Liege | 4000 | Belgium |
| Universitair Ziekenhuis Leuven /ID# 255098 | Recruiting | Leuven | Vlaams-Brabant | 3000 | Belgium |
| Hospital Universite Enfants Reine Fabiola /ID# 255112 | Recruiting | Brussels | 1020 | Belgium |
| UMHAT Sveti Georgi /ID# 255386 | Recruiting | Plovdiv | 4002 | Bulgaria |
| Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384 | Recruiting | Sofia | 1606 | Bulgaria |
| UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 256358 | Recruiting | Varna | 9009 | Bulgaria |
| Alberta Children's Hospital /ID# 255357 | Recruiting | Calgary | Alberta | T3B 6A8 | Canada |
| Edmonton Clinic Health Academy /ID# 255361 | Recruiting | Edmonton | Alberta | T6G 1C9 | Canada |
| BC Children's Hospital /ID# 255359 | Recruiting | Vancouver | British Columbia | V6H 3V4 | Canada |
| London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 258598 | Recruiting | London | Ontario | N6A 5W9 | Canada |
| Beijing Children's Hospital /ID# 256081 | Recruiting | Beijing | Beijing Municipality | 100045 | China |
| Peking University Third Hospital /ID# 255876 | Recruiting | Beijing | Beijing Municipality | 100191 | China |
|
| Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 255428 | Recruiting | Guangzhou | Guangdong | 510620 | China |
| The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 270589 | Recruiting | Guangzhou | Guangdong | 510655 | China |
| Henan Children's Hospital Zhengzhou Children's Hospital /ID# 255562 | Recruiting | Zhengzhou | Henan | 450018 | China |
| Hunan Children's Hospital /ID# 255610 | Recruiting | Changsha | Hunan | 410007 | China |
| Jiangxi Provincial Children's Hospital /ID# 255564 | Recruiting | Nanchang | Jiangxi | 330006 | China |
| Shengjing Hospital of China Medical University /ID# 255563 | Recruiting | Shenyang | Liaoning | 110022 | China |
|
| Children's Hospital of Shanghai /ID# 255531 | Recruiting | Shanghai | Shanghai Municipality | 200062 | China |
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688 | Recruiting | Shanghai | Shanghai Municipality | 200065 | China |
| Vseobecna Fakultni nemocnice v Praze /ID# 256096 | Completed | Prague | Praha 17 | 128 00 | Czechia |
| Fakultni nemocnice Motol a Homolka /ID# 256547 | Completed | Prague | Praha 5 | 150 06 | Czechia |
| CHRU Tours - Hopital Gatien de Clocheville /ID# 255052 | Recruiting | Tours | Centre-Val de Loire | 37044 | France |
| CHU Bordeaux - Hopital Pellegrin /ID# 257060 | Recruiting | Bordeaux | New Aquitaine | 33076 | France |
| CHU Toulouse - Hopital Paule de Viguier /ID# 255609 | Recruiting | Toulouse | Occitanie | 31059 | France |
| Hospices Civils de Lyon - Hôpital Femme Mère Enfant /ID# 255443 | Recruiting | Bron | Rhone | 69500 | France |
| AP-HP - Hopital Necker /ID# 255608 | Recruiting | Paris | 75015 | France |
| Dr. von Haunerschen Kinderspital /ID# 255577 | Recruiting | Munich | Bavaria | 80337 | Germany |
| Universitaetsklinikum Muenster /ID# 256762 | Recruiting | Münster | North Rhine-Westphalia | 48149 | Germany |
| Schneider Children's Medical Center /ID# 254950 | Recruiting | Petah Tikva | Central District | 4920235 | Israel |
| Shaare Zedek Medical Center /ID# 254951 | Recruiting | Jerusalem | Jerusalem | 91031 | Israel |
| IRCCS Istituto Giannina Gaslini /ID# 255262 | Recruiting | Genoa | Genova | 16147 | Italy |
| Azienda Ospedaliera Universitaria Federico II - Naples /ID# 255045 | Recruiting | Naples | Napoli | 80131 | Italy |
| Ospedale Pediatrico Bambino Gesù /ID# 255043 | Recruiting | Rome | Roma | 00165 | Italy |
| Azienda Ospedaliera Universitaria Gaetano Martino /ID# 255044 | Recruiting | Messina | 98125 | Italy |
| Aichi Children'S Health And Medical Center /ID# 272085 | Recruiting | Ōbu | Aichi-ken | 474-8710 | Japan |
| Tsujinaka Hospital - Kashiwanoha /ID# 268409 | Recruiting | Kashiwa-shi | Chiba | 277-0871 | Japan |
| Kurume University Hospital /ID# 268418 | Recruiting | Kurume-shi | Fukuoka | 830-0011 | Japan |
| Gunma University Hospital /ID# 270560 | Recruiting | Maebashi | Gunma | 371-8511 | Japan |
| Japanese Red Cross Kumamoto Hospital /ID# 268586 | Recruiting | Kumamoto | Kumamoto | 861-8520 | Japan |
| Osaka Women's and Children's Hospital /ID# 268419 | Recruiting | Izumi-Shi | Osaka | 594-1101 | Japan |
| Saitama Children's Medical Center /ID# 268410 | Recruiting | Saitama-shi | Saitama | 330-8777 | Japan |
| Institute of Science Tokyo Hospital /ID# 269175 | Recruiting | Bunkyo-ku | Tokyo | 113-8519 | Japan |
| Tokyo Metropolitan Children's Medical Center /ID# 268415 | Recruiting | Fuchu-shi | Tokyo | 183-8561 | Japan |
| National Center For Child Health And Development /ID# 268420 | Recruiting | Setagaya City | Tokyo | 157-8535 | Japan |
| Amsterdam UMC, locatie AMC /ID# 254827 | Recruiting | Amsterdam | North Holland | 1105 AZ | Netherlands |
| Gastromed Sp. z o.o /ID# 255939 | Completed | Torun | Kuyavian-Pomeranian Voivodeship | 87-100 | Poland |
| Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 255938 | Recruiting | Warsaw | Masovian Voivodeship | 04-730 | Poland |
| Puerto Rico Health Institute /ID# 255071 | Recruiting | Dorado | 00646 | Puerto Rico |
| Clinical Research Puerto Rico /ID# 266479 | Recruiting | San Juan | 00909-1711 | Puerto Rico |
| Seoul National University Hospital /ID# 255318 | Recruiting | Seoul | Seoul Teugbyeolsi | 03080 | South Korea |
| Yonsei University Health System Severance Hospital /ID# 256976 | Recruiting | Seoul | Seoul Teugbyeolsi | 03722 | South Korea |
| Samsung Medical Center /ID# 255284 | Recruiting | Seoul | Seoul Teugbyeolsi | 06351 | South Korea |
| Kyungpook National University Chilgok Hospital /ID# 255817 | Recruiting | Daegu | 41404 | South Korea |
| Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 255614 | Recruiting | Ferrol | A Coruna | 15405 | Spain |
| Hospital Infantil Universitario Nino Jesus /ID# 255012 | Recruiting | Madrid | 28009 | Spain |
| Hospital Regional Universitario de Malaga /ID# 257553 | Recruiting | Málaga | 29011 | Spain |
| Sodersjukhuset /ID# 255239 | Recruiting | Stockholm | Stockholm County | 118 83 | Sweden |
| Astrid Lindgrens Barnsjukhus /ID# 255240 | Recruiting | Stockholm | Stockholm County | 171 76 | Sweden |
| Sahlgrenska Universitetssjukhuset /ID# 255236 | Recruiting | Gothenburg | Västra Götaland County | 413 46 | Sweden |
|
| University Children's Hospital Zurich - Eleonorenstiftung /ID# 255337 | Recruiting | Zurich | Canton of Zurich | 8032 | Switzerland |
| Inselspital, Universitaetsspital Bern /ID# 255321 | Recruiting | Bern | 3010 | Switzerland |
| Changhua Christian Hospital /ID# 256082 | Recruiting | Changhua City, Changhua County | 50006 | Taiwan |
| National Taiwan University Hospital /ID# 255679 | Recruiting | Taipei | 100 | Taiwan |
| Gazi University Medical Faculty /ID# 255086 | Recruiting | Ankara | 06560 | Turkey (Türkiye) |
| Sariyer Hamidiye Etfal Eğitim Ve Araştirma Hastanesi /ID# 257143 | Recruiting | Istanbul | 34453 | Turkey (Türkiye) |
| Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 261020 | Recruiting | Istanbul | 34899 | Turkey (Türkiye) |
| Kocaeli University Med Faculty /ID# 256922 | Recruiting | Kocaeli | 41380 | Turkey (Türkiye) |
| Sheffield Children's Hospital NHS Foundation Trust /ID# 255758 | Recruiting | Sheffield | England | S10 2TH | United Kingdom |
|
| Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 255757 | Recruiting | London | Greater London | E1 2ES | United Kingdom |
| Birmingham Women's and Children's NHS Foundation Trust /ID# 255759 | Recruiting | Birmingham | B4 6NH | United Kingdom |
| ID | Term |
|---|---|
| D003424 | Crohn Disease |
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D007410 | Intestinal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000601773 | risankizumab |
Not provided
Not provided
Not provided